Spondyloarthritis & psoriatic arthritis
Type 17-specific immune pathways are active in early spondyloarthritis
Authors' conclusion
These results suggest that adaptive T cell cytokine pathways differ not only between RA and SpA but also seronegative UIA early in the disease process, with a particular activation of Tc17 pathways in early SpA.
Study context
- Population
- Patients with undifferentiated early inflammatory arthritis (EIA) providing synovial fluid samples
- Participants
- 30 patients
- Comparison
- Synovial T-cell cytokine expression by final diagnosis: Spondyloarthritis (SpA) vs seronegative undifferentiated inflammatory arthritis (UIA) vs seropositive rheumatoid arthritis (RA)
- SpAn = 14
- Seronegative UIAn = 10reference
- Seropositive RAn = 6
- Outcome
- Expression of IL-17A, IFNγ and TNFα in synovial CD8+ and CD4+ T cells
Methodological detailsfinal diagnoses ≥12 months after sampling by two independent clinicians blind to study data, flow cytometry
- Final diagnoses ≥12 months after sampling by two independent clinicians blind to study data
- Flow cytometry
Main finding
As reported in the abstract
Synovial T-cell cytokine expression by final diagnosis
- Considerable variation in synovial T cells (Tc17) (IL-17A+CD8+) cell frequencies between patients
- SpA: significant enrichment in percentage of synovial Tc17 cells vs seronegative UIA
- Seropositive RA: few Tc17 cells
- RA synovial fluid (SF): significantly higher percentage of CD8+IFNγ+ T cells vs SpA or seronegative UIA
Original publication
Type 17-specific immune pathways are active in early spondyloarthritis. RMD Open. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →